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Abstract  
Colorectal cancer (CRC) is one of the cancers with highest incidence and mortality in the 
world. In order to decrease these numbers earlier diagnosis, better treatments and better 
surveillance is required. 
In this context, cancer biomarkers arise as important tools useful for diagnosis, monitoring 
disease progression, predicting disease recurrence and therapeutic treatment efficacy. 
Therefore, it is necessary to find new CRC biomarkers highly sensitive and specific to help clinical 
decisions. 
In the last decade, Phospholipase C epsilon (PLCε) has been studied as a possible 
biomarker for CRC, particularly its single nucleotide polymorphism (SNP) rs2274223 has been 
associated with the risk of CRC development. 
In our study, we aimed, not only, to assess the risk of PLCE1 SNP rs2274223 in CRC 
development in a Portuguese population, but also, analyse how this polymorphism affected 
patient’s survival. Furthermore, we also investigated how this polymorphism influenced cellular 
processes such as proliferation, epithelial-to-mesenchymal transition (EMT), angiogenesis and 
inflammation. 
Overall, our results show that PLCE1 SNP rs2274223 A>G is not associated with the risk of 
developing CRC. Furthermore, this polymorphism was not shown to be involved in CRC survival 
of stages I-III and IV patients.  
Moreover, we could not associate this phenotype with any abnormal cellular process. 
In sum, we found by several means that PLCE1 SNP rs2274223 A>G appears to have no 
role on CRC development and progression. Our findings are contrary to most of the published 
reports about this SNP. 
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Resumo 
O cancro colorretal é o quarto cancro mais diagnosticado e o terceiro com maior 
mortalidade no mundo, sendo que em Portugal é o terceiro mais diagnosticado e o segundo 
com maior mortalidade. 
De forma a diminuir a mortalidade associada a esta doença é necessário diagnosticar a 
mesma em estadios iniciais, desenvolver melhores terapêuticas e ainda melhorar o 
acompanhamento da doença. É neste sentido, que os biomarcadores podem desempenhar um 
papel importante. 
Por essa razão, é necessário descobrir novos biomarcadores para cancro colorretal com 
maior sensibilidade e especificidade de forma a complementar e melhorar as decisões clínicas e 
terapêuticas para o doente. 
As fosfolipases C (PLCs) são potenciais biomarcadores que se encontram expressos em 
todas as células do organismo e que participam em variadas funções celulares como 
proliferação, motilidade, invasão e diferenciação. 
A principal função das PLCs é hidrolisar fosfatidilinositol 4,5-bisfosfato (PIP2) existente na 
membrana celular dando origem a diacilglicerol (DAG) e inositol 1,4,5-trisfosfato (IP3). O IP3 é 
importante na regulação dos níveis de cálcio intracelular, enquanto que o DAG é capaz de ativar 
a proteína quinase C (PKC) e as suas vias a jusante.  
Existem 6 famílias de PLCs (PLCβ, PLCγ, PLCδ, PLCη, PLCζ e PLCε), todas elas partilham 
domínios catalíticos comuns, no entanto, também apresentam domínios, estruturas e 
mecanismos de regulação específicos. 
A PLCε tem expressão ubíqua em todos os tecidos, apesar da sua maior expressão se 
verificar no coração, pulmão e colon. Esta enzima apresenta domínios específicos como o 
domínio CDC25 na porção N-terminal e dois domínios de associação a RAS (RA1 e RA2) na porção 
C-terminal. 
O domínio CDC25 foi demonstrado como tendo função de troca de guaninas, portanto 
ativador da proteína RAP1, enquanto os domínios de associação ao RAS, em particular o domínio 
RA2, são importantes para a translocação da enzima do citoplasma para a membrana 
plasmática, onde exerce a sua função. 
Modelos animais transgénicos provaram que a depleção de PLCε pode levar ao 
desenvolvimento de hipertrofia cardíaca e ainda síndrome nefrótico. 
Esta enzima também já foi associada à inflamação da pele, à neuro-inflamação e ao 
cancro. 
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No entanto, o papel desta PLC no cancro é controverso. Se por um lado foi documentado 
que em alguns cancros, como por exemplo do esófago, a PLCε exerce um papel oncogénico, 
noutros, como é o caso do cancro colorretal, a PLCε parece apresentar uma função supressora 
de tumor. 
Nos últimos anos, têm sido vários os estudos que associam a PLCε a cancro colorretal, em 
particular o seu polimorfismo rs2274223 tem sido associado com um risco aumentado de 
desenvolver esta doença. 
Este polimorfismo consiste na substituição de um nucleótido de adenina por uma guanina 
no gene PLCE1, que posteriormente se traduz na substituição de um aminoácido de histidina 
por um de arginina na posição 1927 da enzima, no seu domínio de ligação ao cálcio (C2). 
Este polimorfismo foi sobretudo associado a um aumento do risco de desenvolver cancro 
esofágico e gástrico. 
No entanto, em cancro colorretal, a sua função é controversa. Enquanto que foi possível 
associar este polimorfismo ao desenvolvimento de cancro colorretal na população chinesa e na 
população turca, o mesmo já não foi possível observar numa população lituana e letã. 
No nosso estudo propusemo-nos a verificar se existe alguma associação entre o 
polimorfismo rs2274223 do gene PLCE1 e o desenvolvimento de cancro colorretal, na população 
portuguesa. Para além disso, fomos ainda verificar, pela primeira vez, se este polimorfismo 
poderia ter algum impacto na sobrevida dos doentes com cancro colorretal em estadios I-III e 
em estadio IV. 
Após a genotipagem de 218 pacientes com cancro colorretal e 221 respetivos controlos 
(equiparados para idade e sexo), os nossos resultados mostram que este polimorfismo não se 
associa com um maior risco de desenvolver cancro colorretal em nenhuma das diferentes 
associações que testámos (AA vs. AG p=1, AA vs. GG p=0,66, AA vs. AG+GG p=0,85, GG vs. AG 
p=0,66 e GG vs. AA+AG p=0,68). Apesar de negativo, este resultado vem corroborar os 
resultados dos trabalhos desenvolvidos em populações do norte da europa (lituana e letã), os 
quais também não encontravam correlação deste polimorfismo com o desenvolvimento desta 
doença. 
Estes resultados podem ser explicados pelo facto de inicialmente este polimorfismo ser 
associado ao risco de desenvolver cancro gástrico e esofágico, podendo a PLCε apresentar um 
papel diferente em CRC. Além disso, a maioria dos estudos foi realizado na população chinesa, 
sendo que, existem estudos na população europeia que indicam que este polimorfismo não está 
associado com o risco de desenvolver CRC. 
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Uma das explicações para esta disparidade de resultados em populações diferentes pode 
ser a existência de um menor Linkage Disequilibrium (LD) na população europeia. Desta forma, 
este polimorfismo não seria o responsável pela carcinogénese na população chinesa, mas sim a 
existência de outros polimorfismos com um alto LD. 
Resumindo, diferenças populacionais e de tipo de tumor podem, em parte, justificar a 
diferença dos nossos resultados com os anteriormente publicados. 
Posteriormente, verificámos que, este polimorfismo não influencia a sobrevida dos 
doentes com cancro colorretal nos estadios I-III (p=0,805) em analises uni- e multivariadas 
controlando para as características dos pacientes e do tumor que podem afetar o prognóstico 
da doença como a idade, estadio, grau de diferenciação, localização do tumor, obstrução e ou 
perfuração, invasão vascular, linfática e ou neural e a presença de margens cirúrgicas com tumor 
à altura do diagnóstico. 
Apesar de não existir uma correlação significativa com a sobrevida dos doentes 
diagnosticados em estadio IV após a análise multivariada controlando para a idade, a localização 
do tumor e o órgão onde se detetaram as metástases (p=0,089), os pacientes homozigóticos 
para o alelo G apresentam uma tendência negativa no seu tempo de vida. Uma vez que esta 
análise foi feita com apenas 6 pacientes homozigóticos para este alelo, seria importante 
aumentar este coorte de forma a obter um maior poder estatístico capaz de validar a tendência 
observada.  
É importante referir que na análise multivariada no estadio I-III e no estadio IV o braço GG 
apresenta poucos doentes, pelo que um maior número de doentes neste braço poderiam 
conferir um maior poder estatístico à análise multivariada. 
No entanto, fomos investigar in vitro os processos celulares relevantes para o 
desenvolvimento e progressão de cancro, com o objetivo de compreender melhor o papel deste 
polimorfismo. 
Existem estudos que associam a abolição da PLCε com um aumento da proliferação, com 
um aumento da libertação de fatores angiogénicos como VEGF-A e com um aumento de fatores 
pró-inflamatórios como COX-2, CXCL-1, CXCL-2, TNF-α, IL-1β, IL-6 e STAT3. 
No nosso estudo, para além de abordar a influência da sobre expressão das variantes de 
PLCε wild-type e PLCε mutante (H1927A) nestes processos, analisámos ainda de que forma este 
polimorfismo poderia afetar a atividade fosfolipídica da enzima e a transição 
epitélio-mesênquima (EMT) nas linhas de cancro colorretal HCT116 e DLD1. 
Da análise in vitro verificamos que em termos funcionais, a sobre expressão de PLCε 
wild-type e a sobre expressão da variante PLCε mutante (H1927A) não apresentam diferenças 
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na atividade fosfolipídica da enzima. Contudo, a PLCε apresenta outros domínios funcionais 
específicos como o CDC25 e RA2, que poderão ser afetados por este SNP e que não foram 
testados neste trabalho. 
Relativamente à expressão dos fatores angiogénicos e pró-inflamatórios anteriormente 
mencionados, verificámos que não existem diferenças significativas quando comparamos o 
efeito da sobre expressão da PLCε wild-type e mutante (H1927A). Contudo, a sobre expressão 
da PLCε wild-type não se traduz numa diminuição generalizada dos fatores pró-inflamatórios 
como já foi publicado, com exceção para TNF-α, cuja expressão diminui nas linhas DLD1, e IL-6, 
que diminui nas linhas HCT116 após sobre expressão de ambas as variantes de PLCε. 
Fomos posteriormente verificar o efeito deste polimorfismo na proliferação celular. 
Assim, verificamos que a sobre expressão da PLCε (quer wild-type quer mutante H1927A) 
provoca uma diminuição na proliferação, sendo este resultado concordante com o papel 
supressor de tumor que é atribuído à PLCε neste tipo de tumor. No entanto, não existem 
diferenças na taxa de proliferação entre a sobre expressão da PLCε wild-type e da PLCε mutante 
(H1927A). 
Finalmente, não conseguimos observar diferenças significativas entre o papel da PLCε 
wild-type e da sua forma mutada (H1927A) na expressão de marcadores como a E-caderina, 
N-caderina, Vimentina e Twist importantes no processo de EMT. 
Em suma, o polimorfismo rs2274223 A>G do gene PLCE1 não parece apresentar qualquer 
influência em CRC, uma vez que não verificámos qualquer associação entre o mesmo e o risco 
de desenvolver a doença, a sobrevivência dos pacientes e nenhuma das funções celulares por 
nós testadas (atividade fosfolipídica, proliferação, EMT, inflamação e angiogénese).  
 
 
 
 
 
 
 
 
 
Palavras-chave: Cancro colorretal; Fosfolipase Cε; SNP rs2274223; Risco; Sobrevivência.  
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1. Introduction  
Cancer is a worldwide problem whose incidence and mortality is extremely high in the world, 
affecting every aspect of our society1.  
The efforts made in prevention, earlier diagnoses and development of better treatments has 
contributed to decreased cancer mortality, however the numbers of new cases and deaths related to 
cancer are still alarming.  
In 2004, the Global Burden Disease Report showed that cancer was the 3rd disease with highest 
mortality, only bellow cardiovascular diseases and infectious/parasitic diseases. This report estimated 
that 7.4 million deaths were related to cancer internationally2. 
In 2012, cancer incidence increased to 14.1 million globally3 and it is estimated that 8.2 million 
deaths occurred due this disease3, while in 2015 cancer caused death to 8.8 million people. 
The Global Cancer Observatory (GCO) estimates that in 2018, cancer incidence will rise to 18.1 
million new cases and cause the death of 9.6 million4. 
Unfortunately, in 2040 cancer incidence is expected to reach 29.5 million new cases and the 
global number of deaths is predicted to increase up to 16.4 million4. These numbers can be explain by 
an increase in lifetime expectancy, risk factors exposure, bad lifestyle habits (e.g. smoking), among 
others5. 
Overall, cancer is generically defined by the uncontrolled growth and spread of malignant cells 
to the surrounding tissues which can, ultimately, affect almost any part of the body6. 
There are different types of cancer depending on the organ or tissue where it is formed, the type 
of cells and their driver mechanisms, therefore, different approaches to treat this disease are desired. 
1.1. Colorectal cancer 
Colorectal cancer (CRC) is the 4th most diagnosed and the 3rd with highest mortality in the world. 
In Portugal, CRC is the 3rd most diagnosed and the 2nd with highest mortality for both sexes and 
all ages. 
GCO estimates that in 2018, 1.85 million new cases will be diagnosed, and 880 792 deaths will 
occur. From those, 10 270 new cases and 3 050 deaths will be registered in Portugal. 
It is expected that the global burden of colorectal cancer will increase to more than 3.2 million 
new cases and 1.6 million deaths in 20404. 
1.1.1. Colorectal cancer development 
CRC develops on the large intestine, which is part of the gastrointestinal system7 (Figure 1). 
Colon compose the major part of the large intestine and is formed by 4 portions named 
ascending colon (connects large intestine with the small intestine), transverse colon (connects the right 
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and the left part of the colon), descending colon and sigmoid colon (connects the descending colon 
with rectum and finally with the anus)7. 
The right side of colon (proximal colon) is composed by the ascending and two thirds of the 
transverse colon which developed embryologically from the midgut. While left colon (distal colon) 
develops from the hindgut and is composed by one third of transverse colon, descending colon and 
sigmoid colon7. 
In 1978, Hill et al. proposed the adenoma-carcinoma sequence to describe the transformation 
of normal colorectal epithelium to an adenoma (polyp), proceeding to in situ carcinoma, and ultimately 
to an invasive and metastatic tumour (Figure 2)8. 
There are different types of polyps (Figure 2) and despite they are pre-cancerous not all turn 
into cancer. Nevertheless, due to the risk they represent of becoming malignant (Figure 2) they must 
be removed9.  
The wall of colon and rectum is made of many layers, CRC start spreading from the mucosa layer 
outwards potentially invading blood and/or lymphatic vessels. From this point, cancer cells can spread 
to other parts of the body (metastasize)9. 
 
 
 
 
 
 
 
 
 
1.1.2. Risk factors and drivers of colorectal cancer developing 
Risk factors are characteristics, or substance exposure that increase the chances of a person 
develop a disease or injury. It is important to know which risk factors are associated to CRC 
development because although some are intrinsic, many can be avoided. 
There are many factors pointed to increase the risk of developing this disease including 
overweight or obesity, excessive alcohol consumption, smoking tobacco, consumption of processed 
and red meat, inflammatory bowel diseases, and family history10. However, it is estimated that 90% of 
CRCs diagnosed develop sporadically and only 10% are caused by an inherited predisposition. 
Pedunculated Polyp Sessile Polyp Serrated Polyp 
Figure 2 – Different types of polyps and how they turn into cancer. 
Figure 1 – Gastrointestinal System Anatomy. 
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1.1.2.1 Sporadic colorectal cancer 
Studying colorectal cancer, Fearon Vogelstein described in 1990 that accumulation of multiple 
mutations in epithelial cells were necessary for the acquisition of selective growth advantage11. 
Chromosomal Instability (CIN), microsatellite instability (MSI) and CpG island methylation pathway 
(CIMP) are now considered the three major genetic and epigenetic mechanisms responsible for 
sporadic CRC12,13. 
Chromosomal Instability is the most common sporadic CRC driver and it is defined as the 
accumulation of numerical or structural abnormalities in chromosomes which leads to lost-of-
heterozygosity (LOH) in tumour suppressor loci and or chromosomal rearrangements. This allows the 
accumulation of mutations in critical genes like APC, KRAS, PIK3CA, BRAF, SMAD4, TP53, and others 
that activate pathways important to tumorigenesis13. 
Microsatellite Instability is caused by the abnormal number of microsatellites (short repeat 
sequences of DNA) in cells. The incapacity of cells to correct DNA damage caused by the silencing of 
DNA mismatch repair (MMR) genes leads to the accumulation of microsatellites. When these 
uncorrected microsatellites are in DNA coding regions, they can give rise to frameshift termination and 
consequently protein truncations13. 
CpG Island Methylation Pathway consist in the methylation of the genome in regions rich in 
cytosine (C) and guanine (G) bases that modulate DNA transcription. This modulation may silence 
important tumour suppressor genes and/or activate constitutively oncogenes13. 
1.1.2.2 Hereditary colorectal cancer 
It is important to characterize CRC with hereditary predisposition to identify persons at risk, to 
provide earlier diagnosis and better therapeutic approaches14. 
Germline mutations are responsible for driving hereditary CRC with a manifestation and 
evolution of the disease well characterized in most of the cases. Germline mutation in APC gene leads 
to Familial Adenomatous Polyposis. Mutations in MSH2, MSH6, MLH1 and PMS2 genes lead to Lynch 
Syndrome. Biallelic mutations of MUTYH lead to MUTYH Associated Polyposis. STK11 gene germline 
mutations lead to Peutz-Jeghers Syndrome, while SMAD4 or BMPR1A lead to Juvenile Polyposis 
Syndrome13,14. 
1.1.3. Colorectal cancer screening and diagnosis guidelines 
An earlier diagnosis of CRC is essential to achieve better outcomes for patients with this disease. 
In this context, European Commission (EC) develop a set of guidelines to assure quality in CRC 
screening and diagnosis15. 
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Despite the increasing list of methods to screen for CRC, to date only faecal occult blood test 
(FOBT) is recommended as screening test15.  
Some imaging techniques are being applied instead or to complement the screening of FOBT for 
example sigmoidoscopies and colonoscopies, due to their potential impact to prevent CRC 
development on-site15.  
A positive colorectal cancer must be confirmed pathologically. After a biopsy or surgery, 
pathologists must report every available tissue characteristic.  
In order to do that, the European Society for Medical Oncology (ESMO) developed guidelines 
underlining the information that have a great impact on patient’s prognosis.  
Therefore, pathologists must report16–18: 
a) Morphological description of the specimen; 
b) Surgical procedure carried out; 
c) Definition of tumour site and size; 
d) Presence or absence of macroscopic tumour perforation; 
e) Histological type and grade; 
f) Distance of cancer from resected margins (proximal, distal and radial); 
g) Presence or absence of tumour deposits; 
h) Lymphovascular and/or perineural invasion; 
i) Presence of tumour budding; 
j) Stage TNM by reporting the extension of tumour in the bowel wall (T), the number of lymph 
nodes removed and how many are invaded by cancer cell (N), and finally the involvement of 
other organs (M). 
1.1.4 Colorectal cancer treatment 
To develop the best treatment, it is important to consider the extension of the disease and 
patient’s risk to relapse. 
While stage report is crucial to determine the extension of the disease, other status like 
involvement of resected margins, histological grade, perforation, lymphovacular and/or perineural 
invasion inform the probability of disease relapse16–18. 
Other parameters may also represent a high-risk condition such as mutations and altered 
expression of genes such as TP53, KRAS, BCL2, TGFA, EGFR, proliferation index and aneuploidy18. 
When developing a strategy of treatment, it is also important to consider individual patient’s 
characteristics like physical condition and age. It is important to assess whether patients have 
capability to get through treatment and consider if the treatment will benefit the patient in the lifetime 
left. 
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Normally, in earlier stages of locoregional disease (Stage I) surgery is the only treatment 
applied16,18. In intermediate stages of the disease (Stage II and III) combined chemotherapy (e.g. 
FOLFOX – Fluoropyrimidine plus oxaliplatin) is the first line treatment after surgery (in rectal cancer 
chemotherapy can be combined with radiotherapy). Rectal cancers in stage III have the option to be 
treated with neoadjuvant therapy to diminished the size of tumour before surgery16. 
Finally, in stage IV the treatment will depend on tumour related characteristics (e.g. local of 
metastasis, symptoms, prognostic molecular or biochemical biomarkers), patient related factors (e.g. 
patient fitness condition) and treatment related factors (e.g. toxicity)17. Commonly, a first line 
treatment (e.g. FOLFIRI, FOLFOX normally in combination with cetuximab or bevacizumab) is used to 
shrink the tumour and metastasis and allow resection or ablation. After surgery, patients continue 
treatment with the first line therapy. 
However, not all patients are fit to go under tumour resection, and some of them relapse after 
finishing the adjuvant therapy cycle. In these cases, patients may initiate a second line therapy that 
must be different from the first line treatment. Every time a patient relapses it is necessary to change 
the therapeutic strategy. There is also the possibility to include these patients in clinical trials to test 
new therapeutic approaches17. 
1.1.5  Colorectal cancer biomarkers 
A cancer biomarker is any molecule (e.g. protein, DNA, RNA, etc.) or tumour cell that can be 
found in body fluids or tissue and signalize an abnormal process. Therefore, cancer biomarkers are 
useful to predict cancer development, prognosis or therapeutic response19.  
Table 1 shows the biomarkers recommended by ESMO and/or by American Society for Clinical 
Pathology and their application on the clinic16–18,20. 
Table 1 – Current biomarkers recommended by ESMO and American Society for Clinical Pathology. 
Biomarker Application Location 
FOBT Diagnostic All locations 
CEA Prognosis All locations 
BRAF mutation V600E Prognosis Right colon 
MSH2, MSH6, PMS2 and MLH1 Prognosis Right colon 
NRAS and KRAS mutations Prognosis and therapeutic response All locations 
 
As previously mentioned, FOBT is the only biomarker used in CRC diagnostic15. 
Carcinoembryonic antigen (CEA) is used to monitor patient’s outcome and predict CRC relapses, high 
levels of CEA are correlated with poor prognosis16–18,20. BRAF mutation V600E alongside with mutations 
on MSH2, MSH6, PMS2 and MLH1 are correlated with poor prognosis in right colon cancer17,20. Finally, 
NRAS and KRAS mutations were found to be correlated with poor prognosis and with resistance to 
anti-EGFR therapy17,20. 
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Furthermore, mutations in PIK3CA, loss of PTEN, the levels of EGFR ligands such as amphiregulin, 
epiregulin and TGF-α, the levels of EGFR protein expression, amplification of EGFR and HER2 are seen 
by ESMO as emerging biomarkers for anti-EGFR therapeutic resistance. However,  they do not have, 
so far, the recommendations necessary to be used by clinicians in a regular basis20.  
In CRC is also established that right and left side colon cancers have different prognosis because 
of their different embryological origins, as well as anatomical, histological, genetic and immunological 
characteristics7,21. 
Other promising biomarkers in CRC follow-up are circulating tumour cells (CTC) and circulating 
tumour DNA (ctDNA). In patients with CRC it is possible to find CTC and ctDNA in the blood stream. An 
elevated number of this cells and/or elevated levels of ctDNA is associated with the risk of developing 
metastasis and/or resistance to therapeutic22.  
Although several putative biomarkers have been identified, very few are effectively used in 
clinical practice, therefore, there is still an urgent need for highly selective and specific biomarkers able 
to allow the earlier detection of tumour cells. 
1.2.  Phosphoinositide-specific phospholipase C 
Phosphoinositide-specific phospholipase C (PLC) proteins are putative cancer biomarkers that 
are found in every human cell and are involved in a broad range of regulatory interactions such as cell 
motility, growth and differentiation23,24. 
PLCs are stimulated by specific receptors for hormones, neurotransmitters, antigens, 
components of the extracellular matrix and growth factors25. 
Once stimulated, PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) generating two 
second messengers: diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3)25,26. 
While IP3 is important in cellular Ca2+ regulation, DAG activates protein kinase C (PKC) and its 
downstream pathway. Together, these second messengers are important regulatory factors of a 
variety of biological functions as cell motility, growth, survival, fertilisation and sensory 
transduction25,26.  
13 PLC isozymes were identified and grouped in 6 families (PLCβ, PLCγ, PLCε, PLCδ, PLCη and 
PLCζ) (Figure 3). All these enzymes share common core of domains but have specific structures and 
regulation mechanisms26. 
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Figure 3 – Phosphoinositide-specific phospholipase C family domain organization: Domain organization of PLCε, PLCβ, 
PLCγ,  PLCδ, PLCη and PLCζ. PLC common domains C2 (green), catalytic TIM barrel domain X-Y (red), EF-hands domain 
(yellow) and pleckstrin homology domain (light blue, except for PLC ζ). PLCε specific domains: CDC25 (dark blue), RAS 
association domain (purple). PLCβ specific domain CTD (brown). PLCγ specific domains: nSH2 and cSH2 (pink) and SH3 
(gray). 
PLCβ has 4 isoforms (PLCβ1, PLCβ2, PLCβ3 and PLCβ4) with different patterns of tissue 
distribution. While PLCβ1 and PLCβ3 are expressed in many tissues,  PLCβ2 and PLCβ4 are mainly 
expressed in hematopoietic and neuronal cells, respectively25–27. Moreover, PLCβ have a GTPase 
activating protein function and its specific C terminal domain (CTD) play an important role in 
membrane binding and activation26. 
Defects in PLCβ3 has been associated with atopic dermatitis like skin inflammation and with 
myeloproliferative neoplasms, while PLCβ1 deficiency has been associated with myelodysplastic 
syndromes26. 
PLCγ has 2 isoforms (PLCγ1 and PLCγ2), while PLCγ1 is ubiquitously expressed, PLCγ2 is 
predominantly expressed in hematopoietic cells25,27,28. 
PLCγ has an insert between the catalytic domains X and Y constituted by two PH domains, two 
SH2 domains and a SH3 domain. These domains play a crucial role in PLCγ auto-inhibition and 
activation downstream receptors tyrosine kinases (RTK) such as epithelial growth factor receptor 
(EGFR)25,27,28. Furthermore, PLCγ is important for hematopoietic cell development, especially in 
immune system cells and disfunctions of PLCγ may contribute to development of auto-immune 
disease27,28. 
PLCγ enzymes also contribute to some oncogenic signalling pathways as signal transduction 
downstream of RTK. The overexpression of this enzyme has been related to breast and colon cancers 
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development. Driver mutations in PLCG genes were identified in angiosarcoma, cutaneous T cell 
lymphoma (CTCL) and chronic lymphocytic leukaemia (CLL)28. 
PLCδ has 4 isoforms (PLCδ1, PLCδ2, PLCδ3 and PLCδ4) and it has a broad distribution in all 
tissues. It is speculated that this enzyme may be the prototype of the others PLC. PLCδ only present 
the PLC conserved domains and do not have any unique domain. Deficiency in these enzymes may be 
involved in male infertility and the development of inflammatory skin diseases such as psoriasis and 
contact hypersensitivity27. 
PLCζ is sperm specific, its structure lacks the PH domain and disfunctions on this enzyme leads 
to infertility27. 
PLCη has 2 isoforms (PLCη1 and PLCη2), these isoenzymes are mainly expressed in brain and its 
physiological functions still unknown27. 
1.2.1. Phospholipase C epsilon (PLCε) 
PLCε is broadly expressed in all tissues but has its higher expression in heart, colon and lung29. 
This enzyme has unique domains such a CDC25 domain in the N-terminal region and two 
RAS-Association domains (RA1 and RA2) in the C-terminal region25–27,30–33. 
While the CDC25 domain works as a guanine exchange factor (GEF) for RAP1, the association of 
RAS proteins with the RA2 domain is important for the translocation of this enzyme from cytoplasm to 
the plasma membrane where it exerts its function. Other families of small GTPases able to activate 
PLCε are RAL and RHO families through binding to the catalytic domain of PLCε29. 
Furthermore, PLCε activity can also be stimulated by lysophosphatidic acid (LPA) and thrombin 
receptors through the G-protein subunit Gα12/1325–27,30–33. 
PLCε has been shown to be crucial in the regulation of normal physiology in animal models. For 
example, mouse models depleted of PLCε developed heart hypertrophy in response to 
chronic cardiac stress. Interestingly, this enzyme has been associated with idiopathic dilated 
cardiomyopathy and may be associated with the development of other human cardiac diseases34,35.  
In another study, zebrafishes knockdown for PLCε developed nephrotic syndrome, since this 
enzyme is important to maintain the podocyte filtration barrier30,36. 
This enzyme was also associated with skin inflammation, neuroinflammation and cancer26. 
1.2.1.1. Phospholipase C epsilon and cancer 
PLCε was shown to be involved in cancer development. This enzyme may participate with its 
phospholipase activity in many pathways associated with cancer (for example cell proliferation). On 
the other hand, its GEF and RAS association properties may also influence RAS/MAPK 
pathways30,34,37,38. 
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Many studies suggest that PLCε deregulation may contribute to tumorigenesis by inducing 
inflammation and angiogenesis which facilitates cancer development and maintenance in skin, 
prostate, bladder and in intestine39–44. 
However, the role of PLCε in cancer development and progression is still controversial. For 
example, in skin cancer studies from Bai and co-workers and Martins et al. showed contradictory 
results for PLCε. 
Bai and co-workers report that transgenic mice with PLCε catalytic function deleted had a delay 
on time of tumour development. After a two-stage chemical skin carcinogenesis protocol these mice 
had less tumour burden than mice with full-length PLCε. These findings suggested that PLCε has an 
oncogene function45. 
On the other side, Martins et al. show that PLCε behave as a tumour suppressor. Since mice 
knockout for PLCε had an increased tumour load, bigger tumours and an increased number of Ki67 
positive cells before and after treatment in the two-stage chemical skin carcinogenesis model46. Thus, 
the controversial role of PLCε in this skin mouse model can be, at least, explained by the different 
nature of the transgenic animal, nevertheless more studies are needed in order to clear PLCε role in 
skin cancer. 
However, in esophageal and gastric cancer results seem to be consensual in showing that high 
levels of PLCε expression were associated with tumour progression, which implicates an oncogene role 
of this enzyme47–49. 
In colorectal cancer, PLCε is considered a tumour suppressor protein. Danielsen et al.  showed 
that mRNA levels of PLCE1 are downregulated in tumour tissue when compared with normal tissue, 
they also found that PLCE1 levels were associated with KRAS mutation49,50. In a separate study, Wang 
X. et al. also found that PLCε expression levels were downregulated when compared with colon normal 
tissue samples. Furthermore, they found that PLCε overexpression lead to higher apoptosis rates, 
slower growth and decreased migration ability in cells. PLCε overexpression also formed smaller 
tumours in xenograft mice49,51. 
Therefore, it is overall agreed that depending on the type of tumour, PLCε may have a tumour 
suppressor role or act as an oncogene49 (Figure 4). 
Finally, there are also many studies developed in digestive tract cancers that reports the 
presence of PLCE1 rs2274223 single nucleotide polymorphism (SNP) as a potential risk factor for cancer 
development. 
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Figure 4 – PLCε controversial role in cancer. Figure from Tyutyunnykova A et al. The controversial role of phospholipase C 
epsilon (PLCε) in cancer development and progression, 201749. 
1.2.1.2. Single nucleotide polymorphism rs2274223 in cancer 
Single nucleotide polymorphism rs2274223 consists in the substitution of an adenine by a 
guanine in the position 5781 of human cDNA from PLCE1 gene, which leads to the substitution of an 
histidine by an arginine in the 1927th amino-acid from PLCε, localized on the C2 domain of the 
enzyme52. 
This polymorphism was discovered by Abnet et al.53 in 2010 in a genome-wide association study 
(GWAS), when studying esophageal cancer.  
This SNP was also studied for gastric cancer (GC) by two different groups but with contrary 
results. While Li-Dong Wang et al.54 report in 2010 that rs2274223 is associated with GC development 
in a Chinese Han population, Palmer et al.55 could not find any association between this SNP and GC in 
a Polish population. 
Furthermore, this polymorphism was also associated with gallbladder cancer in a North Indian 
population56. 
There were some retrospective studies that identified an association between rs2274223 and 
CRC development. In 2012, Fen-Xia Li et al.57 reported that while the AG genotype had a malignant 
effect in CRC, the genotype GG seemed to have a protector role. Furthermore, in 2014, Qi Wang et 
al.52 showed that in a Chinese population the phenotypes AG an GG were associate with increased risk 
of developing CRC, they further show that mRNA levels of the polymorphic allele PLCE1 were 
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downregulated when compared to the wild-type mRNA. This could potentially lead to a reduction of 
PLCε enzyme and consequently reduction of its tumour suppressor role, exposing patients to increased 
risk of development of this disease. 
In 2015, Juozas Kupcinskas et al.58 develop the first study in a European population that 
evaluated the association of this SNP with CRC, the results obtained by them show no significant 
association between PLCE1 SNP rs2274223 and CRC. 
However, contrary to those results, in a case-control study developed by Oztas Ezgi et al.59 in 
a Turkish and Caucasian population it was found an association between PLCE1 SNP rs2274223 and 
CRC. 
Overall, the association between SNP rs2274223 and CRC is not consensual and highly 
inconclusive. 
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2. Objectives  
Many studies have explored the association between SNP rs2274223 and CRC. However, it is still 
unclear whether this polymorphism is related with CRC. 
Interesting, most studies were developed in Chinese populations. The only two studies that 
focused on European population had contradictory results. Furthermore, all these studies had focused 
only in the risk of developing CRC leaving unanswered the question of whether the outcome of patients 
with CRC is affected by the presence of this polymorphism. Finally, the functional role of this 
polymorphism in cancer cells was never explored before.  
Therefore, with this project we aimed at studying this polymorphism, not only, in a clinical 
setting, but also, in an in vitro approach. 
Our specific objectives are: 
i. In a clinical setting: 
a) Access the risk of PLCE1 SNP rs2274223 in developing CRC in a Portuguese population; 
b) Determination of polymorphism rs2274223 prognostic value. 
ii. In an in vitro approach: 
a) Determine the influence of this polymorphism in the phospholipase activity; 
b) Determine how this polymorphism affects cells properties. 
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3. Materials and Methods 
3.1 Study Population 
This was a single center case-control study which enrolled 219 patients newly diagnosed with 
CRC and confirmed by histopathology analysis from Hospital de Santa Maria, Centro Hospitalar Lisboa 
Norte, in Lisbon, Portugal. Patient’s blood samples were stored at -80°C, at L. Costa Laboratory 
Biobank. 
We retrospectively collected patient’s information, namely, age at diagnosis, sex, follow-up 
time, tumour location, pathological tumour stage and tumour differentiation status accordingly to 
WHO classification of tumours of the digestive system60, positive margins after surgery (PMAS), 
obstruction or perforation at diagnosis, lymphatic, neural or vascular invasion (LNVI) and KRAS 
mutations (only for Stage IV Patients). Data collection occurred between April 2006 to December 2017 
and was in agreement with data protection principle. 
As healthy controls, 221 samples were requested from Biobanco-IMM, Lisbon Academic Medical 
Centre, Lisbon, Portugal, which were matched for sex and age.  
All control participants and patients agreed to make available their biological material for 
research purposes by filling and signing an Informed Consent. 
3.2. Genomic DNA Extraction and Genotyping 
Patient’s blood samples were collected in ethylenediaminetetra-acetic acid (EDTA) 
anticoagulant tubes and stored at -80°C until genomic DNA (gDNA) extraction. 200μL of blood was 
used to extract gDNA following NZY Blood gDNA Isolation Kit (NZYTech) recommended protocol and 
stored at -20°C until analysis.  
The rs2274223 SNP was genotyped using the TaqMan® SNP Genotyping Assay (Reference: 
C___1947254_1; Applied Biosystems). For allele A probes were marked with VIC, while for allele G 
probes were marked with FAM fluorescence dyes. 
Patient’s and control’s gDNA samples were placed in MicroAmpTM Fast Optical 96-Well Reaction 
Plates following the Wet DNA Delivery Method of Taqman® Genotyping Master Mix Protocol in a 10μL 
reaction: 5μL TaqMan Genotyping Master Mix (2X), 0,5μL TaqMan genotyping assay mix (20X) and 
4,5μL of sample (containing a gDNA concentration between 1 to 20ng/μL). 
The PCR amplification was carried out with an initial pre-denaturation step at 60°C for 1 min and 
a 10 min denaturation at 95°C followed by 40 cycles of denaturation at 95°C for 15 s and 
annealing/extension at 60°C for 1 min, using an Applied Biosystems® 7500 Fast Real-Time PCR System 
according to the manufacturer’s instructions. The 7500 Fast Software v2.0.6 (Applied Biosystems) was 
used for data analysis. 
  14 
Allelic discrimination was measured by ΔRn using ROX as passive reference. 
3.3. Mutagenesis 
In order to test the role of this polymorphism in vitro, rat PLCE1 cloned into pEGFP-C1 vector 
(Clontech) were obtained from Matilda Katan´s Lab at University College London. Site-directed 
mutagenesis was then performed in order to alter the coding of PLCε from arginine to histidine in 
position 1927. Mutagenesis was performed following the NZYMutagenesis kit (NZYTECH) 
recommended protocol using the complementary primers (forward and reverse) designed and 
provided by Invitrogen (Thermofisher) bellow: 
Primer Forward (5’to3’):  
GGAATGAGCAGTTTCTCTTCCACGTTCACTTTGAAGATCTTG 
Primer Reverse(5’to3’):  
CAAGATCTTCAAAGTGAACGTGGAAGAGAAACTGCTCATTCC 
PCR was performed accordingly to manufacturer indications, in the reaction mix for mutagenesis 
1μL of PLCE1 plasmid was used and 2μL of each primer (10μM each). After PCR, template DNA was 
digested with DpnI restriction enzyme PCR product was transformed into NZYStar competent cells. 
Finally, DNA was isolated from different kanamycin resistant colonies using NZYMiniprep (NZYTech) 
and confirmed by sequencing. 
3.4. Cell Culture 
Cos-7 (Cercopithecus aethiops immortalized kidney fibroblast cell line), DLD1 and HCT116 
human colon cancer cell lines were purchased from American Type Culture Collection (ATCC, Virginia, 
USA) and cultured in fresh complete growth medium constitute by Dubelcco’s Modified Eagle’s 
Medium (DMEM; Gibco) supplemented with 10% of Fetal Bovine Serum (FBS; Gibco) and 1% of 
Penicillin-Streptomycin (Pen/Strep; Gibco). Cells were grown at 37°C with 5% of CO2. 
Cos-7, DLD1 and HCT116 cell lines were transfected when were at 60-70% confluence with 
Lipofectamine® 3000 (Thermofisher), using pEGFP-C1-PLCE1 wild-type and mutant (H1927A) vectors, 
following manufacture instructions. Briefly, Lipofectamine® 3000 reagent (1μL), plasmid DNA (1μg) 
and P3000 reagent (2μL) were diluted in Opti-MEM® Medium (Gibco) and incubated for 20min at room 
temperature to create DNA-lipid complexes that were then added to 24-well plate cells in medium 
without serum or antibiotics. Volumes were adjusted for other format plates. For parental control, 
cells were incubated with Lipofectamine®3000 reagents for the same time. Roughly, 3 hours after 
initial transfection, the medium was replaced by fresh complete growth medium. 
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3.5. Cell Viability Assay 
To perform the viability test 3 x 104 DLD1 and HCT116 cells were culture in 24-well plates with 
DMEM supplemented with 10% FBS and 1% Pen/Strep for 24 hours at 37°C until they were at 60-70% 
confluence. At that point, cells were transfected using Lipofectamine® 3000, as previously described. 
24 hours after transfection, medium was changed by 1mL of fresh complete growth medium 
supplemented with 10% alamarBlue® from Invitrogen (Thermofisher). After 3 hours of incubation 
fluorescence was read with an excitation wavelength of 570nm and an emission length of 585nm in 
the Infinite 200 Microplate Reader (Tecan). 
This last step of the procedure was repeated for 3 days. 
3.6. Activity Assay 
To perform the activity assay 2,5 x 105 Cos7 cells were seeded into a 6 well-plate with DMEM 
supplemented with 10% FBS and 1% Pen/Strep for 24 hours at 37°C. At that point, cells were 
transfected using Lipofectamine® 3000 and plasmids coding for PLCε wild-type and mutant (H1927A) 
as previously described. 
48 hours after seeding, cells were washed twice with inositol-free DMEM (USBiological) without 
serum and incubated for 24h in 1,5ml of the same medium supplemented with 0,25% fatty acid free 
bovine serum albumin (BSA, Sigma) and 1,5μCi/ml myo-[2-3H]inositol (PerkinElmer Life Sciences). At 
that time, cells were incubated in 1,2ml of inositol-free DMEM without serum containing 20mM LiCl 
(Sigma) with or without stimulation with 100 ng/ml EGF (Calbiochem®) for 1 hour. 
To lyse cells was added 1,2ml 4,5% perchloric acid (Fluka) and incubated on ice for 30min. 
Samples were centrifuged for 20min at 4000rpm, supernatants were separated from pellets, 
neutralized by addition of 3ml of 0,5M potassium hydroxide/9mM sodium tetraborate (both from 
Sigma) and centrifuged for 20min at 4000rpm. After that, Anion exchange AG1-X8 200–400 columns 
(Bio-Rad) was converted to the formate form by addition of 2M ammonium formate/0,1M formic acid 
(both from Sigma). These columns were equilibrated with water and supernatants were loaded. The 
columns were washed three times with 5ml of 60mM ammonium formate/5mM sodium tetraborate, 
and inositol phosphates were eluted with 5ml of 1,2M ammonium formate/0,1M formic acid. 5ml 
Ultima-Flo scintillation fluid (PerkinElmer Life Sciences) was added to the eluates and the radioactivity 
quantified by liquid scintillation counting. The values represent total inositol phosphates. The pellets 
from the first centrifugation were resuspended in 100μl of water and 375μl of 
chloroform/methanol/HCL (200:100:15) (chloroform and HCL from Sigma and Methanol from Merck), 
plus an additional 125μl of chloroform and 125μl of 0,1M HCL. After vortexing, the samples were 
centrifuged at 2500rpm for 10min. 20μl of the lower phase were placed in a scintillation vial with 2ml 
of Ultima-Flo scintillation fluid and the radioactivity quantified by liquid scintillation counting. The 
  16 
obtained values correspond to radioactivity in total inositol lipids. PLC activity is expressed as the total 
inositol phosphates formed relative to the amount of [3H]myo-inositol in the phospholipid pool. 
3.7. Western Blot 
To perform Western blotting 3 x 106 DLD1 and HCT116 cells were cultured in Petri dishes with 
DMEM supplemented with 10% FBS and 1% Pen/Strep for 24 hours at 37°C until they were at 60-70% 
confluence. At that point, cells were transfected using Lipofectamine® 3000. 
48 hours after transfection, HCT116 and DLD1 cell lines were lysed in lysis buffer (25mM Tris 1M 
pH 7,5 (Sigma), 2mM EDTA 0,5M (Sigma), 10mM 10% Triton (VWR), 1mM TCEP 1M (Sigma), protease 
inhibitor cocktail (Roche) and phosphatase inhibitor cocktail 2 (Sigma)) for 10min on ice. 
Cells with lysis buffer were incubated for 10min on ice, centrifuged by 10min at 12000rpm at 
4°C, and the supernatant transferred to a new tube to quantify proteins concentration. Lysates were 
centrifuged for 10min at 12000rpm at 4°C, and pellets removed. Protein quantification was performed 
using Bradford Reagent (Bio-rad) following manufacturer’s instructions. Briefly, a BSA standard curve 
was initially performed with 0; 0,125; 0,25; 0,5; 0,75; 1; 1,5 and 2 mg/mL concentrations. Absorbance 
was measured in a microplate reader at 595nm. Absorbance of samples was read at the same 
wavelength and concentration extrapolated by BSA standard curve. 
For protein dry transfer, proteins were transferred for nitrocellulose membranes using iBlot™ 2 
Gel Transfer Device from Invitrogen (Thermofisher) for 10min (1min at 20V, 4min ate 23V and 5min at 
25V). 
For wet transfer, proteins were transferred to a nitrocellulose membrane overnight at 40mA 
and at 4°C. 
After the transference, the nitrocellulose membrane was blocked with 5% non-fat milk in TBS 
0,1% Tween20, or in 5% BSA in TBS 0,1% Tween20 (depending on antibody dilution buffer) for 1 hour, 
and then incubated overnight at 4°C with specific primary antibodies (Table 2). 
 
Antibody Dilution Dilution Buffer Source 
Anti-GFP Mouse Monoclonal 
Antibody 
1:1000 
5% w/v Milk, 1X 
TBS, 0.1% Tween Sigma-Aldrich Anti-GFP 
Anti-β-actin Mouse Monoclonal 
Antibody 
1:5000 
5% w/v Milk, 1X 
TBS, 0.1% Tween 
Abcam Anti-beta Actin antibody 
[mAbcam 8226] (ab8226)  
Anti-STAT3 (124H6) Rabbit 
Monoclonal Antibody 
1:1000 
5% w/v Milk, 1X 
TBS, 0.1% Tween 
Cell signaling® STAT3 (124H6) 
Mouse mAb 9139 
Anti-phospho-STAT3 (Ser727) 
Rabbit Monoclonal Antibody 
1:1000 
5% w/v BSA, 1X 
TBS, 0.1% Tween 
Abcam Anti-STAT3 (phospho 
S727) antibody [E121-31] 
(ab32143) 
Table 2 – List of antibodies used in Western Blot. 
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Next day, after wash with TBS 0,1% Tween20, the nitrocellulose membrane was incubated for 1 
hour at room temperature with horseradish peroxidase-conjugated (HRP) specific secondary 
antibodies. 
Proteins were detected using Amersham ECL Western Blotting Detection Reagent (GE 
Healthcare Life Sciences), according to manufacturer’s instructions. Signal was detected on 
radiographic film (Fujifilm), using Curix60 (AGFA). 
3.8. Real-time Reverse Transcriptase Polymerase Chain Reaction (RT-qPCR) 
To perform RT-qPCR, 5 x 105 DLD1 and HCT116 cells were cultured in 6-well plates with DMEM 
supplemented with 10% FBS and 1% Pen/Strep for 24 hours at 37°C until they were at 60-70% 
confluence. At that point, cells were transfected using Lipofectamine®3000, as previously described. 
For total RNA extraction, cells were lysed 48 hours after transfection following NZY Total RNA 
Isolation Kit protocol (NZYTech) and RNA was quantified using NanoDrop 2000™ (Thermo Fisher 
Scientific).  
After total RNA extraction, cDNA synthesis was performed following the protocol of NZY 
M-MuLV First-Strand cDNA Synthesis Kit, separate oligos from NZYTech using Oligo(dT)18. 
Finally, NZY RNase H (E. coli) was added to the samples to degrade the RNA that was not 
converted in cDNA. 
After cDNA synthesis, it was performed the qPCR. Samples were analysed in triplicates in Corbett 
Rotor-Gene 6000 (QIAGEN Rotor-Gene Q). To each reaction, Sybr Green (NZY qPCR Green Master Mix 
(2x); NZYTECH), nuclease-free water, and primers were mixed with cDNA from samples into qPCR tubes 
from Qiagen. 
Primers were purchased from Invitrogen (Thermo Fisher), except the specific Mouse PLCE1 
primer (PPM28139A-200) which is from QIAGEN. The Table 3 is a list of the primers used in qPCR, this 
list also shows the primers forward and reverse sequences used. Relative mRNA expression levels were 
normalized to endogenous GAPDH and calculated using the 2-ΔΔCT method. 
Primer Name Forward Sequence (5’→3’) Reverse Sequence (5’→3’) 
GAPDH AAC ATC ATC CCT GCC TCT ACT G TTG ACA AAG TGG TCG TTG AGG 
CDH1 (E-cadherin) GGA AAC TCT CTC GGT CCA GCC CCT CAA GTG TTA CCT CAA 
CDH2 (N-cadherin) GCC CCT CAA GTG TTA CCT CAA AGC CGA GTG ATG GTC CAA TTT 
VIM (Vimentin) GAA AAC ACC CTG CAA TCT T CCT GGA TTT CCT CTT CGT G 
TWIST1 (TWIST) CCG GAG ACC TAG ATG TCA TTG CCA CGC CCT GTT TCT TTG 
VEGFA GGA GGA GGG CAG AAT CAT CAC GGT CTC GAT TGG ATG GCA GT 
IL1B (IL-1β) GCC CTA AAC AGA TGA AGT GCT C GAA CCA GCA TCT TCC TCA G 
IL6 (IL-6) TAC CCC CAG GAG AAG ATT CC TTT TCT GCC AGT GCC TCT TT 
TNF (TNF-α) TCA GCC TCT TCT CCT TCC TG GCC AGA GGG CTG ATT AGA GA 
PTGS2 (COX-2) CCC AGG GCT CAA ACA TGA TG GTC TAG CCA GAG TTT CAC CG 
Table 3 – List of primers used in qPCR (all primers in this list are for human cDNA). 
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3.9. Statistical Analysis 
Statistical analysis was performed in IBM® SPSS® software package, version 24.0 (IBM 
Corporation, New York, United States). Descriptive statistics were tabulated according to PLCE1 
genotype. For continuous variables (e.g. follow-up months), median and interquartile range were 
calculated. On the other hand, for categorical variables, proportions were calculated and differences 
were tested using Chi-Square test. 
To calculate the odds of developing colorectal cancer according to PLCE1 genotype (categorical 
nominal variable), the odds ratio was calculated with respective confidence interval (95%), and its 
significance was accessed by Chi-Square test. A logistic regression was further performed to adjust the 
effect estimate (odds ratio) to known risk factors for CRC, as age (categorical ordinal variable) and sex 
(categorical nominal variable). 
Given the unfavourable prognostic implications and biological differences of metastatic cancer, 
survival outcomes were reported in two independent groups defined as a function of the stage at time 
of diagnosis (I-III and IV) and patients were analysed in two arms (AA/AG vs. GG) in univariate and 
multivariate analysis.  
Overall survival (OS) was calculated using the Kaplan-Meier method and graphical 
representations of survival outcomes were reported using Kaplan-Meier graphs. Survival curves of 
both arms were analysed by log rank test. To explore the prognostic implications of PLCE1 genotype 
(categorical nominal variable), a univariate and multivariate Cox proportional hazards model was built 
controlling for known prognostic patients and tumour characteristics, as age (categorical ordinal 
variable), stage, grade, tumour location, obstruction and perforation, vascular, lymphatic and or neural 
invasion and the presence of unclear margins at time of diagnosis (categorical nominal variables). In 
stage IV patients, the multivariate analysis included tumour location, the location of organ metastasis 
(categorical nominal variables) and age. Median follow-up was balanced throughout the PLCE1 
genotypes. 
To analyse significant differences in the PLCε Activity Assay and in the relative expression of 
genes mPLCE1, hCDH1, hCDH2, hVIM, hTWIST, hVEGFA, hIL1B, hIL6, hTNF, hPTGS2, hCXCL1 and hCXCL2 
between controls and the polymorphisms AA and GG we performed one-way ANOVA. To determine 
significant differences in the Cell Viability Assay we performed two-way ANOVA. Tukey Test were 
performed to determine which conditions had significative differences.  
CXCL1 (CXCL-1) GTC CGT GGC CAC TGA ACT GGG GAT GCA GGA TTG AGG C 
CXCL2 (CXCL-2) GCA GGG AAT TCA CCT CAA GA GGA TTT GCC ATT TTT CAG CA 
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4. Results and Discussion 
4.1. Role of PLCE1 rs2274223 polymorphism in the risk of developing colorectal cancer 
Most of the studies about PLCE1 rs2274223 polymorphism approach the importance of this SNP 
in the risk of developing colorectal cancer. However, there are contradictory results reported52,57–59.  
In order to unveil the importance of this polymorphism in the risk of developing colorectal 
cancer, we enrolled 218 patients with colorectal cancer and 221 healthy controls that were matched 
by sex and age (Table 4). 
 
Table 4 – Demographical characteristics of patients with CRC and healthy controls enrolled in this study. Differences 
between groups were accessed using independent T-test for Age (Years) and Chi-square test for Age (Rank years), Sex. N 
represents the number of samples, ±SD represents age standard deviation. p-value were calculated using 95% confidence 
interval. 
 
 
 
 
 
 
 
 
Genomic DNA was extracted from patient’s blood sample and genomic DNA from healthy 
controls was provided to us from Biobanco-IMM. Genotyping was assessed by real-time PCR and the 
allelic discrimination of patients vs. control samples were plotted considering ΔRn values for allele A 
and for allele G (Figure 5A and 5B). 
 
 
  Patients Controls p-value 
Number of Samples 218 221 / 
Age (Years) 
Mean 68,78 66,26 
0,011 
±SD 11,381 8,437 
Age (Rank years) 
N (%) 
<65 69 (31,7%) 87 (39,4%) 
0,110 
≥65 149 (68,3%) 134 (60,6%) 
Sex 
N (%) 
Male 131 (60,1%) 129 (58,4%) 
0,771 
Female 89 (39,9%) 92 (41,6%) 
Figure 5 – Allelic discrimination of PLCE1 rs2274223 A>G polymorphism. Plots were drawn for CRC patients (A) and 
controls (B) according to ΔRn of allele A (VIC) and allele G (FAM). ROX was the reference dye.  
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These results allowed to determine the SNP distribution in patients with CRC and healthy 
controls (Table 5), which was not significantly different, both in the univariate (p-value= 0,882; χ2-test 
of the difference between the three genotype groups), and multivariate analysis controlling for age 
and sex (p-value=0,839; Logistic Regression) (Table 5). Thus, genotype homozygotic for allele A was 
seen in about 45% of patients and 43% of controls, whereas the heterozygote genotype was shown 
approximately in 42% to 43% of both groups and homozygote for allele G was seen in 13% and 15% of 
patients and controls, respectively. 
Furthermore, the genotype frequencies of the polymorphism in the healthy control group 
followed the Hardy-Weinberg Equilibrium (p-value=0,32), which states that allele and genotype 
frequencies in a population remain constant from generation to generation in the absence of other 
evolutionary influences. Therefore, our results show that our control population was not affected by 
evolutionary processes of mutation, migration or selection. 
 
Table 5 -Genotype distribution of PLCE1 gene rs2274223 polymorphism in patient with CRC and healthy control. 
Genotype distribution was accessed by Chi-square test and a logistic regression was performed to adjust for sex and age. N 
represent the number of samples. p-value were calculated using 95% confidence interval. 
 
Nevertheless, the risk of developing CRC for each group (AA vs. AG; AA vs. GG; GG vs. AG), 
comparing the most common genotype with the other two genotypes together (AA vs. AG+GG) and 
comparing the rarest genotype with the other two (GG vs. AA+AG), do not show any significant 
difference between the genotypes, both in the univariate and multivariate (adjusting for age and sex) 
analyses (Table 6). 
In any case, if a trend can be inferred from these results, although not significant, is a possible 
protective role of the GG genotype. Our results are in agreement with what was found by Kupcinskas, 
J. et al.58, who showed no association of this SNP with CRC risk, but opposite to Wang, Q. et al.52 and 
Ezgi, O. et al.59.  
 
 
 
 
    
Patients Controls p-value 
Adjusted 
p-value 
Genotype 
AA N (%) 97 (44,5%) 96 (43,4%) 
0,882 0,839 AG N (%) 93 (42,7%) 93 (42,1%) 
GG N (%) 28 (12,8%) 32 (14,5%) 
    Adjusted for age and sex 
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Table 6 – Association between PLCE1 genotypes and risk of CRC in patients with CRC and healthy controls. The number of 
samples used in the determination of risk is represented by N. Risk of developing colorectal cancer was accessed by odds 
ratio (OR) with a Confidence Interval of 95% (CI), p-value was calculated by two-sided Fisher’s exact test with a 5% 
significance (α) and a logistic regression was performed to adjust for sex and age. 
4.2. Prognostic value of PLCE1 rs2274223 polymorphism  
In order to access the prognostic value of PLCE1 polymorphism rs2274223, we compared the 
overall survival (OS) of the different PLCE1 genotypes in our patient’s population. Since some studies 
point the genotype GG as having the worst outcome, we analysed OS in two arms, comparing 
genotypes AA and AG against GG61. 
Furthermore, given that the prognosis of patients in stage I-III is very distinct from patients 
diagnosed in stage IV, we analysed the role of PLCE1 polymorphism rs2274223 separately in these two 
groups of patients.  
4.2.1. PLCE1 rs2274223 polymorphism prognostic value in stage I-III colorectal cancer patients 
In patients with stage I-III CRC there are demographic, clinical and pathological characteristics 
such as age, sex, stage, grade, location, obstruction and/or perforation at time of diagnosis, 
lymphatic/neural and/or vascular invasion (LNVI) and the presence of positive margins after surgery 
(PMAS), that may have an impact in the prognosis of patients. 
Therefore, before accessing the prognostic value of PLCE1 rs2274223 polymorphism in stage I-
III CRC patients it was necessary to analyse if these characteristics were associated with this 
polymorphism (Table 7).  
Table 7 shows that there is no association between this SNP and any demographic, clinical or 
pathological characteristic investigated. 
 
 
 
 
         Adjusted 
    
N OR CI 
p-value 
(α=0,05) 
OR CI 
p-value 
(α=0,05) 
G
e
n
o
ty
p
e
 
AA vs GG 253 1,16 0,65 – 2,07 0,66 0,88 0,49 – 1,59 0,68 
AA vs. AG 379 1,01 0,68 – 1,51 1,00 1,01 0,67 – 1,52 0,95 
AA vs. AG+GG 439 1,04 0,72 – 1,51 0,85 1,03 0,70 – 1,50 0,89 
GG vs. AG 246 0,88 0,49 – 1,56 0,66 0,84 0,47 – 1,51 0,56 
GG vs. AA+AG 439 0,87 0,50 – 1,50 0,68 0,85 0,49 – 1,47 0,56 
        Adjusted for age and sex 
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Table 7 - Clinical and demographic characteristics of stage I to III CRC patients. Clinical and demographic characteristics of 
CRC patients and their association with genotype were analysed by independent T-test for age, and by Chi-square test for 
sex, stage, grade, location, obstruction/perforation, LVNI and PMAS. N represents the number of samples, P25 and P75 
represent the 25th and 75th percentiles of follow-up and age. p-value were calculated using 95% confidence interval. 
  
Genotype   
AA/AG GG p-value 
Number of Patients                            
N (%) 
149 (87,1%) 22 (12,9%) / 
Follow up 
(Months) 
Median 71,475 
/ 
P25 - P75 47,475 - 93,279 
Median 72,623 65,508 
/ 
P25 - P75 45,279 - 93,295 53,959 - 92,508 
Age (Years) 
Median 72 66,5 
0,460 
P25 - P75 63,0 - 77,5 62,00 - 72,25 
Sex                       
N (%) 
Male 86 (57,7%) 16 (72,7%) 
0,245 
Female 63 (42,3%) 6 (27,3%) 
Stage                   
N (%) 
I 44 (29,5%) 3 (13,6%) 
0,192 II 50 (33,6%) 7 (31,8%) 
III 55 (36,9%) 12 (54,5%) 
Grade                   
N (%) 
G1 43 (28,9%) 5 (22,7%) 
0,817 G2 85 (57,0%) 14 (63,6%) 
G3 21 (14,1%) 3 (13,6%) 
Location              
N (%) 
Right Colon 46 (30,9%) 2 (9,1%) 
0,071 Left Colon 46 (30,9%) 7 (31,8%) 
Rectum 57 (38,2%) 13 (59,1%) 
Obstruction 
Perforation          
N (%) 
No 93 (62,4%) 12 (54,5%) 
0,631 Yes 53 (35,6%) 9 (40,9%) 
Unknown 3 (2,0%) 1 (4,5%) 
LVNI                   
N (%) 
No 119 (79,9%) 20 (90,9%) 
0,207 Yes 27 (18,1%) 1 (4,5%) 
Unknown 3 (2,0%) 1 (4,5%) 
PMAS                
N (%) 
No 139 (93,3%) 20 (90,9%) 
1,000 Yes 7 (4,7%) 1 (4,5%) 
Unknown 3 (2,0%) 1 (4,5%) 
 
Following this analysis, we tested the implications of PLCE1 genotypes on the OS of patients (by 
univariate and multivariate models) (Figure 6).  
Therefore, the Kaplan-Meier (KM) representation of OS according to PLCE1 genotype. This group 
of CRC patients was composed by 171 patients, of which 149 had the genotypes AA or AG (87,1%), 
while 22 had the genotype GG (12,9%). 
Patients were followed for a maximum of 117,57 months (approximately 10 years), with a 
median follow-up time of 71,475 months (P25=47,475; P75=93,279). During this period 52 patients 
with the genotypes AA or AG and 7 patients with the genotype GG died (35,1% and 31,8% respectively). 
However, the median survival was not reached for any of the two groups. 
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Our results indicate that the genotype had no influence in the patient’s outcome in a univariate 
analysis of OS (log-rank test p-value= 0,805; HR= 1,105; CI= 0,502 – 2,433). After adjustment for age, 
stage, grade, tumour location, obstruction and perforation, LVNI and PMAS at time of diagnosis (model 
1, Table 8), the genotype is still seen not associated with patient’s outcome (p-value= 0,992; HR= 1,005; 
CI= 0,409 – 2,468). Finally, a second model of analysis was performed accounting only for the variables 
that had shown association with the outcome on model 1 (Table 8, Age p-value= 0,001; Stage p-value= 
0,006; LVNI p-value= 0,007). Confirming the previous results, model 2 shows that PLCE1 genotype has 
no influence on patient’s outcome (p-value= 0,793; HR= 1,124; CI= 0,469 – 2,693). 
However, this multivariate analysis had a small number of patients with GG genotype and, for 
that reason, increasing the number of this patients could empower our analysis. 
Overall, our results show for the first time that PLCE1 rs2274223 polymorphism has no influence 
on patient’s survival is stage I-III. 
 
 
 
 
 
 
 
 
  
Univariate 1,105 0,502 - 2,433 0,805
Adjusted Model 1 1,005 0,409 - 2,468 0,992
Adjusted Model 2 1,124 0,469 - 2,693 0,793
HR CI P
Figure 6 – Survival curve and univariate and multivariate analysis of OS from patients with CRC from stage I to III. Univariate 
analysis was performed comparing patient’s genotypes AA/AG vs. GG according to their alive status across the time. N events (%) 
represents the number and percentage of patients that died in this analysis, N.R. represents that median survival was not reached. 
Hazard Ratio (HR) and p-value (P) were calculated with a 95% confidence interval (CI). Multivariate analysis was used to compare 
both arms (AA/AG vs. GG) in the adjusted models 1 and 2, which were calculated by cox regression with 95% confidence interval. 
AA/AG GG
N events (%) 52 (34,9%) 7 (31,8%)
Median 
Survival
N.R. N.R.
Genotype
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Table 8 – Models used for multivariate analysis of OS from patients with CRC from stage I to III. In Model 1 the variables 
used to calculate survival were genotype, age, stage, grade, tumour location, LVNI, obstruction/perforation and PMAS. In 
Model 2 the variables used to calculate survival were genotype, age, stage and LVNI. Adjustment to both models were 
performed using Cox regression. Hazard Ratio (HR) and p-value were calculated with a 95% confidence interval (CI). 
Model 1 Variables in the Equation Model 2 Variables in the Equation 
 
HR 
95% CI 
p-value 
 
HR 
95% CI 
p-value 
Lower Upper Lower Upper 
Genotype 
AA+AG vs. GG 1,01 0,41 2,47 0,992 
Genotype 
AA+AG vs. GG 1,12 0,47 2,69 0,793 
Age 1,05 1,02 1,09 0,001 Age 1,06 1,03 1,09 0,000 
Stage I       0,006 Stage I       0,003 
Stage II 0,28 0,11 0,69 0,006 Stage II 0,27 0,12 0,63 0,002 
Stage III 0,46 0,24 0,89 0,020 Stage III 0,50 0,28 0,91 0,024 
Grade 1       0,619 LVNI 0,43 0,24 0,79 0,006 
Grade 2 0,70 0,29 1,65 0,411        
Grade 3 0,71 0,34 1,47 0,352         
Left Colon       0,633         
Right Colon 1,41 0,68 2,94 0,352         
Rectum 1,29 0,62 2,69 0,493         
LVNI 0,41 0,21 0,78 0,007         
Obstruction 
Perforation 
1,19 0,65 2,15 0,575 
        
PMAS 0,49 0,16 1,51 0,213         
4.2.2. PLCE1 rs2274223 polymorphism prognostic value in stage IV colorectal cancer patients 
It is equally necessary to account for the clinical, demographic and pathological characteristics 
that influence prognosis of patients with CRC stage IV such as age, sex, tumour location, presence of 
KRAS mutations and metastasis location, prior the analysis of PLCE1 rs2274223 polymorphism 
association with patient’s OS. 
The Table 9 shows the association between clinical and demographic characteristics and PLCE1 
rs2274223 polymorphism.  
 
Table 9 – Clinical and demographic characteristics of CRC patients between stage IV associated with PLCE1 rs2274223 
polymorphism. Clinical and demographic characteristics of CRC patients and their association with genotype were analysed 
by independent T-test for age, and by Chi-square test for sex, location, KRAS mutations and organ of metastasis. p-value 
were calculated using 95% confidence interval. 
 Genotype 
 
AA/AG GG p-value 
Number of Patients 
N (%) 
39 (86,7%) 6 (13,3%) / 
OS Follow up 
(Months) 
Median 30,033 
/ 
P25 - P75 16,836 - 60,574 
Median 32,131 14,885 
P25 - P75 21,639 - 60,656 6,869 - 40,279 
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Age (Years) 
Median 67 77 
0,024 
P25 - P75 54 - 73 68,5 - 83,25 
Sex                         
N (%) 
Male 24 (61,5%) 3 (50,0%) 
0,670 
Female 15 (38,5%) 3 (50,0%) 
Location                
N (%) 
Left Colon 16 (41,0%) 3 (50,0%) 
0,555 Right Colon 8 (20,5%) 2 (33,3%) 
Rectum 15 (38,5%) 1 (16,7%) 
KRAS mutations 
N (%) 
No 18 (46,2%) 1 (16,7%) 
0,312 Yes 13 (33,3%) 3 (50,0%) 
Unknown 8 (20,5%) 2 (33,3%) 
Metastasis 
Organ  
N (%) 
Liver Only 22 (56,4%) 6 (100%)  
Lung Only 2 (5,1%) 0  
Multiple 11 (28,2%) 0  
Other 4 (10,3%) 0  
 
In stage IV CRC patients, PLCE1 genotype was associated with age (p=0,024), being GG patients, 
in average, 10 years older than AA/AG CRC patients. The other clinical and demographic characteristics 
analysed had no association with patient’s PLCE1 genotype. 
Kaplan-Meier curves of these patients are represented on Figure 7 and the adjustment model 
of the multivariate analysis can be consulted on Table 10. 
 
 
Figure 7 – Survival curve, univariate and multivariate analysis of OS from patients with CRC from stage IV. Univariate 
analysis was performed comparing patient’s genotypes AA/AG vs. GG according to their alive status across the time. N 
events (%) represents the number and percentage of patients that died in this analysis. Hazard Ratio (HR) and p-value (P) 
were calculated with a 95% confidence interval (CI). Multivariate analysis was used to compare both arms (AA/AG vs. GG) 
in the adjusted model and was calculated by cox regression with 95% confidence interval. 
  26 
In this cohort, 45 CRC patients were analysed, of which 39 had the genotypes AA or AG (86,7%), 
while 6 had the genotype GG (13,3%). Patients were followed for a maximum of 106,03 months 
(approximately 9 years), with a median follow-up time of 30,033, months (P25= 16,836; P75= 60,574). 
During this period 28 patients with the genotypes AA or AG and 5 patients with the genotype GG died 
(71,8% and 83,3% respectively). 
Both groups reached the median survival which was 32,121 months (CI= 21,700 – 42,562) for 
genotypes AA or AG and 14,066 months (CI= 4,975 – 23,156) for genotype GG. 
In patients at stage IV, genotype had a significant influence in the univariate analysis of OS (log-
rank test p-value = 0,044; HR= 0,385; CI= 0,142 – 0,975). However, given that association of PLCE1 
genotype was seen with age, a multivariate model was needed to effectively infer the value of PLCE1 
rs2274223 polymorphism in OS. After adjustment for age, tumour location and metastasis location, 
PLCE1 genotype is not statistically significative for patient’s survival (adjustment model p-value= 0,089; 
HR= 0,389; CI= 0,131 – 1,155). 
KRAS mutation status was excluded from the adjustment model since there were a considerable 
number of patients with missing information, which could lead to incorrect results. 
Altogether, these results suggest that PLCE1 rs2274223 polymorphism may not influence 
patient’s survival is stage IV. Although a trend for negative outcome may be seen. Given that in this 
analysis only 6 patients were homozygotic for this allele, increasing our cohort could effectively answer 
the question of whether PLCE1 SNP rs2274223 contributes to the outcome of CRC patients in stage IV. 
 
Table 10 – Models used for multivariate analysis of OS from patients with CRC from stage IV. In this adjustment model the 
variables used to calculate survival were genotype, age, tumour location and organ of metastasis. The adjustment model 
was performed using Cox regression. Hazard Ratio (HR) and p-value were calculated with a 95% confidence interval (CI). 
Adjustment Model Variables 
  HR 
95% CI for HR  
Lower Upper p-value 
Genotype                   
AA+AG vs GG 
0,389 0,131 1,155 0,089 
Age 1,037 1,000 1,074 0,048 
Left Colon    0,071 
Right Colon 2,620 1,055 6,503 0,038 
Rectum 3,174 1,072 9,398 0,037 
Liver Metastasis    0,601 
Lung Metastasis 0,381 0,091 1,587 0,185 
Multiple 
Metastasis 
0,000 0,000  0,975 
Other Metastasis 0,377 0,084 1,688 0,202 
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4.3. PLCε activity after wild-type and mutant (H1927A) PLCE1 overexpression 
As described before, PLCε is responsible for cleaving PIP2 into the second messengers IP3 and 
DAG. 
We investigated whether PLCE1 rs2274223 polymorphism could affect PLCε lipase activity 
(Figure 8).  
In order to do that, we performed a lipase catalytic assay in Cos-7 cells overexpressing wild-type 
and mutant (H1927A) PLCε (Figure 8A). This assay allows to quantify IP3 release upon PLC activation. 
Therefore, as expected, our results show that overexpressing PLCε in Cos-7 cells increases 
significantly PLCε activity when compared to non-transfected cells (wild-type p-value=0,0014; mutant 
p-value=0,0008). Furthermore, after stimulation of cells with EGF, is seen an increase in PLC activity 
given that activation of EGF intracellular pathway activates PLCs (wild-type p-value=0,0005; mutant 
p-value=0,0002). 
Finally, we can see that PLCε mutant has a slightly higher activity than the wild-type enzyme in 
cells without stimulation, and this activity is even higher after EGF stimulation (without stimulation: 
mutant mean=16,24; wild-type mean=12,63; with stimulation: mutant mean=39,24; wild-type 
mean=34,74; p=0,045). However, expression of the PLCε mutant (H1927A) was also higher than 
expression of wild-type protein (Figure8B). These results, therefore, suggest that H1927A mutation is 
likely to affect protein expression rather than its activity.  
 
 
Figure 8 – PLCε Activity Assay. PLCε activity was measured by the percentage of IP release. The assay was performed in two 
independent experiments, each experiment was performed in duplicates. %IP Release data is present as mean ± SD and 
p-values (p) were calculated using one-way ANOVA and Tukey’s multiple comparisons tests with a CI of 95% (A), Protein 
levels of PLCε were detected by mouse anti-GFP and β-actin was used as loading control in western blot (B). 
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4.4. PLCE1 rs2274223 polymorphism role in EMT biomarkers 
Although we didn’t see differences in activity between PLCε wild-type and mutant (h1927A), we 
sought to analyse if PLCε enzymes could affect epithelial-to-mesenchymal transition (EMT) markers in 
CRC cell lines by qRT-PCR (Figure 9). 
 
Figure 9 – Relative expression analysis of EMT Biomarkers. Western blot of PLCε overexpression with anti-GFP, β-actin was 
used as loading control (A), relative expression of PLCε (B), E-cadherin (C), N-cadherin (D), Vimentin (E) and TWIST (F) in 
DLD1 and HCT116 cell lines after overexpression of PLCε wild-type and mutant (H1927A). As controls were used non-
transfected cells. The relative expression of these markers was calculated using GAPDH as standard reference. The data is 
present as the mean ± SD. The data shown in this figure is representative of two independent assays performed in triplicate 
(N=3). In the figures p-value is represented by (p) and was calculated by one-way ANOVA and Tukey’s multiple comparisons 
tests with a CI of 95%. 
Figure 9 shows that PLCE1 overexpression with wild-type and mutant (H1927A) plasmid 
increased the levels of protein and mRNA of PLCε both in DLD1 and HCT116 cell lines (Figure 9A and 
9B, respectively) but had no effect in the relative expression of mRNA in CDH1 (E-cadherin), CDH2 (N-
cadherin), VIM (Vimentin) and TWIST1 (TWIST) (Figure 9C, 9D, 9E and 9F). Furthermore, in CRC cell 
lines, expression of PLCε wild-type and mutant (h1927A) seem identical. 
Overall, these results suggest that H1927A mutation of PLCε does not affect the EMT process of 
CRC cells. 
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4.5. PLCE1 rs2274223 polymorphism role in inflammation and angiogenesis 
Mingzhen Li et al. reported that PLCε promotes intestinal tumorigenesis of ApcMin/+ mice through 
augmentation of inflammation and angiogenesis biomarkers, such as COX-2, CXCL-1 and CXCL-2 and 
VEGF-A, respectively40. 
Furthermore, STAT3 transcription factor was also associated with PLCε by Xue Yang et al. which 
report that knockdown of PLCε decreased the levels of STAT3 phosphorylation in bladder cancer cell 
lines42. Given that STAT3 pathway is responsible for the transcription of a variety of genes involved in 
the regulation of critical functions, including cell differentiation, proliferation, apoptosis, angiogenesis, 
metastasis, and immune responses (mainly inflammation)62. The same study, also reported a decrease 
in the levels of IL1B, IL6, TNFA42. 
Therefore, it is important to investigate if PLCε mutant (H1927A) protein affects the regulation 
and expression of these inflammatory and angiogenic markers differently than the wild type variant 
(Figure 10). 
 
Figure 10 – Analysis of inflammatory and angiogenic biomarkers. Relative expression of VEGFA (A), relative expression of 
TNFA (B), IL1B (C), IL6 (D), PTGS2 (E), CXCL1 (F) and CXCL2 (G) in DLD1 and HCT116 cell lines after overexpression of PLCε 
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wild-type and mutant (H1927A). As controls were used non-transfected cells. The relative expression of these markers was 
calculated using GAPDH as standard reference. Relative expression data is present as the mean ± SD. The data shown in this 
figure is representative of two independent assays performed in triplicate (N=3). In the figures p-value is represented by (p) 
and was calculated by one-way ANOVA and Tukey’s multiple comparisons tests with a CI of 95%. STAT3 and p-STAT3 were 
accessed by western blot in HCT116 and DLD1 cell lines (H). β-actin was used as loading control. The assay for western blot 
was performed in duplicate (N=2).  
We analysed the relative expression of mRNA of VEGFA, TNFA, IL1B, IL6, PTGS2 (COX-2), CXCL1 
and CXCL2 (Figures 10A-G respectively), and the protein levels of STAT3 and p-STAT3 (Figure 10H). 
We could not find any difference in the mRNA levels of these cytokines or phosphorylation status 
of STAT3 when comparing PLCε wild-type and mutant (H1927A). 
 We found, however, that PLCε overexpression of both variants significantly decreased TNFA in 
DLD1 cell lines and IL6 in HCT116 cell lines.  
Altogether, these results indicate that PLCε genotype does not seem to have a role in 
inflammatory tumour initiation and angiogenesis in colorectal cancer. 
4.6. PLCE1 rs2274223 polymorphism role in cell proliferation 
Finally, we wanted to see if this polymorphism could affect cell proliferation. In order to do that, 
we performed a cell viability assay after overexpressing PLCε wild-type and the mutant (H1927A) in 
HCT116 and DLD1 cell lines (Figure 11A and 11B, respectively). 
Although overexpression of both variants of PLCε seem to decrease cell proliferation in HCT116 
and DLD1 cell lines, we could not see any difference between PLCε variants (p-value=0,3473 and 
p-value=0,8532, respectively). 
Therefore, these results are in agreement with a possible tumour suppressive role for PLCε, but 
PLCE1 rs2274223 polymorphism has no impact in cell proliferation. 
 
Figure 11 – Cell Viability Assay. Cell viability assay was performed with alamarBlue® in HCT116 (A) and DLD1 (B) cell lines 
after overexpression of PLCε wild-type and mutant (H1927A). As controls were used non-transfected cells. Relative 
proliferation data is present as the mean ± SD. The data shown in this figure is representative of two independent assays. In 
the figures p-value is represented by (p) and was calculated by two-way ANOVA and Tukey’s multiple comparisons tests 
with a CI of 95%. 
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5. Conclusions and Future Perspectives 
CRC is a disease which incidence and mortality has been raising along the last years. Therefore, 
it is important to diagnose CRC the earliest possible to improve patient’s outcome. 
Only after diagnosis, the best treatment is defined and patients are followed in all the course of 
the disease. For that reason, identifying new biomarkers will help diagnosis, treatment definition and 
patient’s follow-up. 
PLCs have been studied as possible new biomarkers28. One of these PLCs is PLCε. Despite, it role 
in cancer be controversial, this enzyme is seen as tumour suppressor enzyme in colorectal cancer49–51.  
In the last decade, PLCE1 SNP rs2274223 association with colorectal cancer has been studied 
with contradictory results49,52,58,59,61,63. 
Initially this polymorphism was associated with the risk of developing gastric and esophageal 
cancer47,53,54,64.  In our study we show that PLCE1 SNP rs2274223 is not associated with an increased risk 
of developing CRC. Therefore, it is possible that PLCε plays a different role in CRC. 
This result is opposite to most of the studies present, so far, for this polymorphism47,52-59,61,62,64. 
It is also important to refer that most of these studies approached Chinese populations52–54,57,63,64 and 
there are studies in other populations with contradictory results55,58. This could be explained by the 
existence of a lower Linkage Disequilibrium65 (LD) in other populations, which would mean that another 
polymorphism with a higher LD could be responsible for tumorigenesis in Chinese population, instead 
of PLCE1 SNP rs2274223. 
Furthermore, we analysed how this polymorphism could have an influence in patient’s survival.  
After analysing OS of patients at stage I-III and IV by univariate and multivariate analysis 
comparing arm AA/AG with GG and analysing Kaplan-Meier curves with log rank test, our findings 
suggest that PLCE1 SNP rs2274223 is not associated with patient’s survival. Moreover, in the OS analysis 
of patients at stage IV, those who were homozygotic for allele G had a negative trend on survival time.  
However, in both analysis a small number of patients homozygotic for allele GG were analysed 
(22 in stage I-III and 6 in stage IV) and for that reason a larger cohort could empower the results of 
univariate and multivariate analysis and clarify if PLCE1 SNP rs2274223 has, or not, a prognostic value 
in CRC patients in stage I-III and in stage IV.  
Based on these results, we analysed in vitro how this polymorphism could influence PLCε 
phospholipase activity and cell functions such as cell proliferation, angiogenesis and immune responses. 
First, we show that overexpressing PLCε wild-type and mutant (H1927A) enzymes did not 
influence PLCε phospholipase activity in Cos-7 cell line. However, this enzyme has other functional 
domains, such as CDC25 and RA2 domains, that were not approached in our study and might be 
affected by this SNP.  
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Next, we analysed how overexpressing PLCε with wild-type and mutant (H1927A) impact EMT. 
In order to do that, we analysed the mRNA expression levels of CDH1 (E-cadherin), CDH2 (N-cadherin), 
VIM (Vimentin) and TWIST1 (TWIST). We could not see any difference between the overexpression of 
wild-type and mutant (H1927A) in any of these EMT biomarkers, which suggest that PLCε enzymes have 
no influence in EMT. 
Since, there are studies reporting that PLCε affects inflammation and angiogenesis we decided 
to investigate how this polymorphism could influence the mRNA expression levels of VEGFA, PTGS2 
(COX-2), TNFA, CXCL1, CXCL2, IL1B e IL640,42. Our results show that overexpressing wild-type and mutant 
(H1927A) PLCε did not affect angiogenic biomarker mRNA expression VEGFA. These results also suggest 
that despite overexpressing both variants of PLCε lead to a decrease in the expression of TNFA in DLD1 
and a decrease of expression of IL6 in HCT116 cell lines, there were no difference of expression between 
the wild-type and the mutant (H1927A) form of PLCε. Furthermore, we could not see any difference in 
the expression of PTGS2, CXCL1, CXCL2 and IL1B, between control cells and after PLCε overexpression 
of wild-type and mutant (H1927A) forms. 
We also analysed the STAT3 pathway, since some studies showed that PLCε knockdown could 
decrease STAT3 phosphorylation42. This pathway has shown to have a role in cell differentiation, 
proliferation, apoptosis, angiogenesis, metastasis, and immune responses62. STAT3 and p-STAT3 
protein levels were not affected, in western blot, by PLCε overexpression of wild-type and mutant 
(H1927A) protein. Which indicates that PLCε has no influence on STAT3 pathway in CRC cell lines. 
Overall, these results are consistent with what we saw in the OS of CRC patients at stage I-III. 
Finally, using alamarBlue®, we accessed how the overexpression of PLCε wild-type and mutant 
(H1927A) was affecting proliferation. PLCε overexpression decreased cell proliferation, which confirms 
that this enzyme act as a tumour suppressor. However, there were no significative differences in cell 
proliferation between PLCε wild-type and mutant (H1927A). This result shows that cell proliferation is 
not affect by PLCε rs2274223 polymorphism. 
In resume, our results are consistent, since this study shows that PLCE1 SNP rs2274223 does not 
increase the risk of CRC development, does not influence statistically patient’s survival (although a 
trend was seen in patients at stage IV homozygotic for allele G), have no effect on cell proliferation, 
EMT, angiogenesis and inflammation.  
Ultimately, this study suggests that PLCE1 SNP rs2274223 may not have a role in CRC 
development and progression.  
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